Patent estate

Sun Pharmaceutical Industries — Patent Portfolio

1 drug with active patents · 8 active patents · 0 expired · 0 biologics with BPCIA exclusivity

AI-enriched 8/8 patents with grounded plain-English summaries · sourced from FDA Orange Book + Purple Book · updated 2026-05-18

§
Strategic Patent Estate Brief
AI-grounded executive summary · generated 2026-05-16

Verdict Sun Pharmaceutical Industries' portfolio is moderately strong, with a significant cliff year in 2027 and no revenue at risk in the next 5 years.

Portfolio overview Sun Pharmaceutical Industries has a relatively small portfolio with a total of 6 drugs, of which only 1 has patents. The company has a total of 8 US patents, all of which are active. The average vulnerability score of the company's patents is 72, indicating a moderate level of vulnerability. Out of the total patents, none are considered ironclad, while 5 are considered vulnerable.

Cliff calendar In 2027, 1 drug will lose exclusivity, including Winlevi. This marks a significant cliff year for the company. Additionally, 5 drugs lose exclusivity in 2028 including [sample names not available in the JSON].

Most exposed drugs The top drug facing near-term loss of exclusivity is Winlevi, with an earliest active patent expiry date of 2027-01-12, an average vulnerability score of 72, and no annual revenue data available. This drug has 8 patents and is considered vulnerable.

Biologic exclusivity Sun Pharmaceutical Industries has no biologics in its portfolio, and therefore, there are no biologics with BPCIA 12-year reference product exclusivity.

Strategic implications The company has no revenue at risk in the next 5 years. However, the loss of exclusivity for Winlevi in 2027 may require the company to consider lifecycle moves such as subQ switches, label extensions, or combination filings to maintain revenue.

Sources: FDA Orange Book · FDA Purple Book · INPADOC family · USPTO · vulnerability scoring. Not legal advice.

Loss of exclusivity calendar · next 12 years

Drugs facing US patent or BPCIA biologic exclusivity loss per year. Click any year to see the broader cliff calendar for the industry.

1 2027 1 2028 1 2029 1 2030

Patent estate by drug

Winlevi (CLASCOTERONE)

Cliff 2027 · 1y
Method of Use 5 Formulation 3
  • US12337002 Vuln 88 2028-07-24
    This patent protects a new enzymatic process for making certain compounds, including a new crystalline form of the active ingredient in the drug Winlevi.
  • US11207332 Vuln 83 2028-11-20
    This patent protects a new enzymatic process for making certain compounds, including a new crystalline form of the active ingredient in the drug Winlevi.
  • US8143240 Vuln 80 2027-01-12
    This patent protects the use of 17α,21-dihydroxypregna-4,9-diene-3,20-dione and 17α,21-dihydroxypregna-4-ene-3,20-dione 17 and/or 21 esters as antiandrogenic agents.
See all 8 patents →

Patent classification breakdown · active patents

By US patent type. Method-of-use patents are most vulnerable to design-around; composition-of-matter patents are the strongest protection.

  • Method of Use 5 patents
  • Formulation 3 patents

Sources

  • FDA Orange Book — small-molecule patents listed against approved NDAs.
  • FDA Purple Book — biologic BPCIA 12-year reference product exclusivity.
  • USPTO Patent Public Search — title, abstract, claim text grounding.
  • AI summaries generated by Drug Landscape, grounded in source claim text.

Patent term extensions (PTR, SPC, pediatric exclusivity) may shift effective expiry. Not legal advice.

Track Sun Pharmaceutical Industries's patent estate

Daily alerts when vulnerability scores shift, patents expire, or IPRs are filed. Free tier: 3 watches. Pro tier (£199/mo): 50 watches + daily AI Pharma IP Brief.

↓ CSV export